Skip to content

Trial Summary

BGB-A1217 is a humanized, IgG1 monoclonal antibody against TIGIT. Tislelizumab is a humanized, IgG4-variant monoclonal antibody against PD-1. This study tests the safety and anti-tumor effect of BGB-A1217 in combination with tislelizumab in patients with advanced solid tumors.

Acronym:

BGB-900-105

ACTRN/NCT /ethics:

NCT04047862

Scientific title:

Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors

Sponsor / Cooperative group:

BeiGene

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2019-08-26
Anticipated End Date2021-04-05

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Nimit Singhal
Recruitment StatusNot Yet Recruiting